Advantagene
Advantagene, a biotechnology company, develops and commercializes cancer immunotherapy drugs.
| Date | Investors | Amount | Round |
|---|---|---|---|
| investor | €0.0 | round | |
| N/A | €0.0 | round | |
| investor | €0.0 | round | |
N/A | Series C | ||
| Total Funding | 000k | ||
Related Content
Advantagene, operating as Candel Therapeutics, is a privately held biopharmaceutical company based in the Boston area. The company is dedicated to extending and improving the lives of cancer patients through the development of innovative cancer immunotherapies. Their core technology, Gene Mediated Cytotoxic GMCI, is designed to stimulate the patient's immune system to naturally combat cancer.
Advantagene primarily serves patients suffering from various types of cancer, including prostate and brain cancer. The company operates in the biopharmaceutical market, focusing on cutting-edge cancer treatment solutions.
The business model revolves around conducting clinical trials to validate the efficacy of their therapies, securing regulatory approvals, and eventually commercializing their treatments. Revenue is generated through partnerships, licensing agreements, and potentially direct sales of their approved therapies.
Keywords: cancer immunotherapy, biopharmaceutical, Gene Mediated Cytotoxic GMCI, clinical trials, prostate cancer, brain cancer, immune response, innovative treatments, Boston area, privately held.